Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients

Purified human menopausal gonadotropin (HMG) is a natural product extracted from the urine of postmenopausal women that contains pituitary follicle-stimulating hormone (FSH), luteinizing hormone (LH), and a small amount of human chorionic gonadotropin (HCG). Here we retrospectively conducted a clini...

Full description

Bibliographic Details
Main Authors: Rui Hua, Lan Ma, Hong Li
Format: Article
Language:English
Published: Hindawi Limited 2013-01-01
Series:International Journal of Reproductive Medicine
Online Access:http://dx.doi.org/10.1155/2013/135258
id doaj-e079c720b54641fe898a1e3f84ae4766
record_format Article
spelling doaj-e079c720b54641fe898a1e3f84ae47662020-11-25T02:11:58ZengHindawi LimitedInternational Journal of Reproductive Medicine2314-57572013-01-01201310.1155/2013/135258135258Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile PatientsRui Hua0Lan Ma1Hong Li2Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, ChinaCenter for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, ChinaCenter for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, ChinaPurified human menopausal gonadotropin (HMG) is a natural product extracted from the urine of postmenopausal women that contains pituitary follicle-stimulating hormone (FSH), luteinizing hormone (LH), and a small amount of human chorionic gonadotropin (HCG). Here we retrospectively conducted a clinical pharmaceutical study on a cohort of normogonadotropic infertile patients addressed to long GnRH-agonist protocol with serum LH concentration ranging from 0.5 IU/L to 1.5 IU/L during the midfollicle phase, aiming at evaluating the effects of purified HMG supplementation during ovarian stimulation. There was no significant difference in either the basic clinical features of the patients or the pregnancy rate (71.4% versus 66.3%, ) or other related indicators of pregnancy outcome. However, there was a higher level of serum oestradiol (E2) on the day of human chorionic gonadotropin (HCG) ( IU/L versus  IU/L, ) but lower fertilization rate (89.1% versus 69.6%, ) in patients getting HMG supplementation and a higher risk of developing ovarian hyperstimulation syndrome (OHSS). We suppose that exogenous LH supplementation is not needed when serum LH concentration of the midfollicle phase is around 0.5–1.5 IU/L during the long GnRH-agonist protocol. Adding exogenous HMG may decrease the fertilization rate and increase the risk of developing OHSS.http://dx.doi.org/10.1155/2013/135258
collection DOAJ
language English
format Article
sources DOAJ
author Rui Hua
Lan Ma
Hong Li
spellingShingle Rui Hua
Lan Ma
Hong Li
Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Journal of Reproductive Medicine
author_facet Rui Hua
Lan Ma
Hong Li
author_sort Rui Hua
title Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
title_short Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
title_full Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
title_fullStr Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
title_full_unstemmed Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
title_sort clinical effects of a natural extract of urinary human menopausal gonadotrophin in normogonadotropic infertile patients
publisher Hindawi Limited
series International Journal of Reproductive Medicine
issn 2314-5757
publishDate 2013-01-01
description Purified human menopausal gonadotropin (HMG) is a natural product extracted from the urine of postmenopausal women that contains pituitary follicle-stimulating hormone (FSH), luteinizing hormone (LH), and a small amount of human chorionic gonadotropin (HCG). Here we retrospectively conducted a clinical pharmaceutical study on a cohort of normogonadotropic infertile patients addressed to long GnRH-agonist protocol with serum LH concentration ranging from 0.5 IU/L to 1.5 IU/L during the midfollicle phase, aiming at evaluating the effects of purified HMG supplementation during ovarian stimulation. There was no significant difference in either the basic clinical features of the patients or the pregnancy rate (71.4% versus 66.3%, ) or other related indicators of pregnancy outcome. However, there was a higher level of serum oestradiol (E2) on the day of human chorionic gonadotropin (HCG) ( IU/L versus  IU/L, ) but lower fertilization rate (89.1% versus 69.6%, ) in patients getting HMG supplementation and a higher risk of developing ovarian hyperstimulation syndrome (OHSS). We suppose that exogenous LH supplementation is not needed when serum LH concentration of the midfollicle phase is around 0.5–1.5 IU/L during the long GnRH-agonist protocol. Adding exogenous HMG may decrease the fertilization rate and increase the risk of developing OHSS.
url http://dx.doi.org/10.1155/2013/135258
work_keys_str_mv AT ruihua clinicaleffectsofanaturalextractofurinaryhumanmenopausalgonadotrophininnormogonadotropicinfertilepatients
AT lanma clinicaleffectsofanaturalextractofurinaryhumanmenopausalgonadotrophininnormogonadotropicinfertilepatients
AT hongli clinicaleffectsofanaturalextractofurinaryhumanmenopausalgonadotrophininnormogonadotropicinfertilepatients
_version_ 1724911494189023232